<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.</h2>
    <div class="badge">2025-09-15T20:10:00+00:00</div>
    <ul>
      <li>Caution – CE marked since 2019.</li>
<li>FDA approved in August 2025 as prescription-only device.</li>
<li>Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021.</li>
<li>Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019.</li>
<li>Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc.</li>
<li>8,700,183, 9,415,215, and 9,415,216.</li>
<li>Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.\n• Caution – CE marked since 2019.\n• FDA approved in August 2025 as prescription-only device.\n• Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021.\n• Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019.\n• Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc.\n• 8,700,183, 9,415,215, and 9,415,216.\n• Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/nyxoah-files-patent-infringement-lawsuit-201000143.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>